Surgical treatment of neuroblastoma: Twenty-three years of experience at a single institution

Surgery Today

Volumn 44, Issue 3, 2014, Pages 517-525

  Koivusalo, A I ^a,b   Pakarinen, M P ^a   Rintala, R J ^a   Saarinen Pihkala, U M ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Chemotherapy; Neuroblastoma; Surgical resection; Survival

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; MELPHALAN; THIOTEPA; VINCRISTINE;

ADOLESCENT; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CHILD; FEMALE; GENE AMPLIFICATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFANT; INTESTINE OBSTRUCTION; LAPAROTOMY; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIPLE ORGAN FAILURE; NECROSIS; NEUROBLASTOMA; ONCOGENE C MYB; OVERALL SURVIVAL; PATIENT SATISFACTION; PRESCHOOL CHILD; SCHOOL CHILD; SURGICAL APPROACH; THORACOSCOPY; THORACOTOMY; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INDUCTION CHEMOTHERAPY; INFANT; MALE; NEOADJUVANT THERAPY; NEOPLASM STAGING; NEUROBLASTOMA; PHOSPHOPROTEINS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME; XENOPUS PROTEINS;

EID: 84896725108     PISSN: 09411291     EISSN: 14362813     Source Type: Journal    
DOI: 10.1007/s00595-013-0576-7     Document Type: Article

References (20)

1. Pritchard J, Cotterill SJ, Germond SM, Imeson J, de Kraker J, Jones DR. High dose melphalan in the treatment of advanced neuroblastoma: results of a randomised trial (ENSG-1) by the European Neuroblastoma Study Group. Pediatr Blood Cancer. 2005;44:348-57.
2. Berthold F, Boos J, Burdach S, Erttmann R, Henze G, Hermann J, et al. Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial. Lancet Oncol. 2005;6:649-58.
3. Matthay KK, Reynolds CP, Seeger RC, Shimada H, Adkins ES, Haas-Kogan D, et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. J Clin Oncol. 2009;27:1007-13.
4. Simon T, Hero B, Faldum A, Handgretinger R, Schrappe M, Klingebiel T, et al. Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy. BMC Cancer. 2011;11:21.
5. Rich BS, McEvoy MP, Kelly NE, Oh E, Abramson SJ, Price AP, et al. Resectability and operative morbidity after chemotherapy in neuroblastoma patients with encasement of major visceral arteries. J Pediatr Surg. 2011;46:103-7.
6. Warmann SW, Seitz G, Schaefer JF, Scheel-Walter HG, Leuschner I, Fuchs J. Vascular encasement as element of risk stratification in abdominal neuroblastoma. Surg Oncol. 2011;20:231-5.
7. Ross SL, Greenwald BM, Howell JD, Pon S, Rutigliano DN, Spicyn N, et al. Outcomes following thoracoabdominal resection of neuroblastoma. Pediatr Crit Care Med. 2009;10:681-6.
8. Monclair T, Brodeur GM, Ambros PF, Brisse HJ, Cecchetto G, Holmes K, et al. The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol. 2009;27(2):298-303.
9. Tajiri T, Souzaki R, Kinoshita Y, Koga Y, Suminoe A, Hara T, et al. Implications of surgical intervention in the treatment of neuroblastomas: 20-year experience of a single institution. Surg Today. 2012;42:220-4.
10. Saarinen UM, Wikström S, Mäkipernaa A, Lanning M, Perkkiö M, Hovi L, et al. In vivo purging of bone marrow in children with poor-risk neuroblastoma for marrow collection and autologous bone marrow transplantation. J Clin Oncol. 1996;14:2791-802.
11. Saarinen-Pihkala U, Hovi L, Koivusalo AI, Jahnukainen K, Karikoski R, Sariola H, et al. Thiotepa and Melphalan based single tandem and triple high dose therapy and autologous stem cell transplantation for high risk neuroblastoma. Pediatr Blood Cancer. 2012;59:1190-7.
12. Brodeur GM, Pritchard J, Berthold F, Carlsen N, Castel V, Castleberry RP, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993;11:1466-77.
13. Iehara T, Hosoi H, Akazawa K, Matsumoto Y, Yamamoto K, Suita S, et al. MYCN gene amplification is a powerful prognostic factor even in infantile neuroblastoma detected by mass screening. Br J Cancer. 2006;94:1510-5.
14. von Schweinitz D, Hero B, Berthold F. The impact of surgical radicality on outcome in childhood neuroblastoma. Eur J Pediatr Surg. 2002;12:402-9.
15. Adkins ES, Sawin R, Gerbing RB, London WB, Matthay KK, Haase GM. Efficacy of complete resection for high-risk neuroblastoma: a Children's Cancer Group study. J Pediatr Surg. 2004;39:931-6.
16. Escobar MA, Grosfeld JL, Powell RL, West KW, Scherer LR 3rd, Fallon RJ, et al. Long-term outcomes in patients with stage IV neuroblastoma. J Pediatr Surg. 2006;41:377-81.
17. La Quaglia MP, Kushner BH, Su W, Heller G, Kramer K, Abramson S, et al. The impact of gross total resection on local control and survival in high-risk neuroblastoma. J Pediatr Surg. 2004;39:412-7.
18. Castel V, Tovar JA, Costa E, Cuadros J, Ruiz A, Rollan V, et al. The role of surgery in stage IV neuroblastoma. J Pediatr Surg. 2002;37:1574-8.
19. Rich BS, McEvoy MP, LaQuaglia MP, Wolden SL, et al. Local control, survival, and operative morbidity and mortality after re-resection, and intraoperative radiation therapy for recurrent or persistent primary high-risk neuroblastoma. J Pediatr Surg. 2011;46:97-102.
20. Kuroda T, Saeki M, Honna T, Masaki H, Tsunematsu Y. Clinical significance of intensive surgery with intraoperative radiation for advanced neuroblastoma: does it really make sense? J Pediatr Surg. 2003;38:1735-8.